Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort

Patients with cancer are presumed to be at increased risk of severe COVID-19 outcomes due to underlying malignancy and treatment-induced immunosuppression Of the first 178 patients managed for COVID-19 at the Gustave Roussy Cancer Centre, 125 (70 2%) were hospitalized, 47 (26 4%) developed clinical worsening and 31 (17 4%) died An age of over 70 years, smoking status, metastatic disease, cytotoxic chemotherapy and an Eastern Cooperative Oncology Group score of ≥2 at the last visit were the strongest determinants of increased risk of death In multivariable analysis, the Eastern Cooperative Oncology Group score remained the only predictor of death In contrast, immunotherapy, hormone therapy and targeted therapy did not increase clinical worsening or death risk Biomarker studies found that C-reactive protein and lactate dehydrogenase levels were significantly associated with an increased risk of clinical worsening, while C-reactive protein and D-dimer levels were associated with an increased risk of death COVID-19 management impacted the oncological treatment strategy, inducing a median 20 d delay in 41% of patients and adaptation of the therapeutic strategy in 30% of patients